mRNA Cancer Vaccine: Moderna-Merck Melanoma Shot Cuts Recurrence 49% in Landmark Trial
In a landmark achievement that oncologists are calling a turning point in cancer treatment, Moderna and Merck announced on August 19, 2026, that their combined mRNA-based cancer vaccine significantly reduced melanoma recurrence